Comprehensive Edaravone Clinical Program Data Published

Wings Presenting Sponsor, Mitsubishi Tanabe Pharma America, Inc. has made its groundbreaking Edaravone study available to researchers.  Edaravone, sold under the Radicava and Radicut names, is the first ALS drug approved by the FDA in 15 years.

Mitsubishi Tanabe Pharma America, Inc. today announced that the comprehensive clinical development program data for edaravone in the treatment of amyotrophic lateral sclerosis (ALS) have been published as a supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (ALSFTD), a leading journal for ALS and FTD research.

The supplement, Edaravone in ALS, provides ALS specialists and researchers a full review of edaravone's 13-year clinical development program, offering a comprehensive overview of the rationale and progression by which researchers were able to demonstrate edaravone's clinical benefit. In a therapeutic arena as devastating and difficult as ALS, which has been challenged by negative trials for many therapeutic agents, key learnings from this development program may be applicable to other future ALS clinical research. 

Edaravone in ALS provides valuable insight into the process by which the sponsor conducted an extensive 13-year clinical development program leading to approval for patients in Japan and South Korea in 2015 – and the United Statesin 2017.

To view the supplement, please click here:
http://www.tandfonline.com/toc/iafd20/18/sup1?nav=tocList